Drug-induced parkinsonism

Neurologist

Volumn 8, Issue 6, 2002, Pages 363-370

  Van Gerpen, J A ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Drug induced parkinsonism; Neuroleptics; Parkinson's disease; Parkinsonism

Indexed keywords

ACETOPHENAZINE; ALIMEMAZINE; AMPHOTERICIN B; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; BUTYROPHENONE; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; CLEBOPRIDE; ESTROGEN; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; MESORIDAZINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PIPERAZINE; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; THIETHYLPERAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID;

CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG SURVEILLANCE PROGRAM; HUMAN; IATROGENIC DISEASE; MEDLINE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

EID: 0036854499     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-200211000-00006     Document Type: Review

References (130)

1. Quinn NP. Parkinsonism: Recognition and differential diagnosis. BMJ. 1995;310:447-452.
2. Fahn S, Przedborski S. Parkinsonism. In: Rowland LP, ed. Merritt's Neurology Philadelphia: Lippincott Williams and Wilkins; 2000:679-693.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological, and neurochemical correlation. J Neurol Sci. 1973;20: 415-455.
4. Molho ES, Factor SA. Secondary causes of parkinsonsim. In: Adler CH, Ahlskog JE, eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. Totowa, NJ: Humana Press; 2000:211-214.
5. Steck H. Le syndrome extrapyramidal et diencephalique an cours de traitments an largactil et an serpasil. Ann Med Psychol (Paris). 1954;2: 737-744.
6. Diederich NJ, Goetz CG. Drug-induced movement disorders. Neurol Clin. 1998;16:125-140.
7. Marti-Masso JF, Poza JJ, Lopez de Munian A. Drugs inducing or aggravating parkinsonism: A review. Therapie. 1996;51:568-577.
8. Arblaster CA, Lakie M, Mutch WJ, et al. A study of the early signs of drug-induced parkinsonism. J Neurol Neurosurg Psychiatry. 1993;56: 301-303.
9. Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: A review. Fundam Clin Pharmacol. 1994;8:293-306.
10. Klawans HL, Bergen D, Bruyn GW. Prolonged drug-induced parkinsonism. Neurology. 1973;35:368-377.
11. Melamed E, Achiron A, Shapira A, et al. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy. Clin Neuropharmacol. 1991;14:273-278.
12. Eichelbaum M, Kroemer HK, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett. 1992;64-65:115-122.
13. Negrotti A, Calzetti S, Sasso E. Calcium-entry blockers-induced parkinsonism: Possible role of inherited susceptibility. Neurotoxicology. 1992;13:261-264.
14. Tanner CM. Occupational and environmental causes of parkinsonism. Occup Med. 1992;7:503-513.
15. Rajput AH, Uitti RJ, Stem W, et al. Geography, drinking water chemistry, pesticides, herbicides, and the etiology of Parkinson's disease. Can J Neurol Sci. 1987;14:414-418.
16. Barbeau A. Mangenese and extrapyramidal disorders. Neurotoxicology. 1984;5:13-16.
17. Jenner P. Parkinson's disease, pesticides, and mitochondrial dysfunction. Trends Neurosci. 2001;24:245-247.
18. Aaserud O, Hommeren OJ, Tvedt B, et al. Carbon disulfide exposure and neurotoxic sequelae among viscose rayon workers. Am J Ind Med. 1990;18:25-37.
19. Marti-Masso JF, Carrera N, Urtasun M. Drug-induced parkinsonism: A growing list [letter]. Mov Disord. 1993;8:125.
20. Hansen TE, Brown WL, Weigel RM, et al. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry. 1992;14:340-344.
21. Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274:1780-1782.
22. Ganzini L, Casey DE, Hoffman WF. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153:1469-1475.
23. Pranzatelli MR, Mott SH, Pavlakis SG. Clinical spectrum of secondary parkinsonism in childhood: A reversible disorder. Pediatr Neurol. 1994; 10:131-140.
24. Sanders DB, Howard JF. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, et al, eds. Neurology in Clinical Practice. Boston: Butterworth Heinemann; 2000:2167-2186.
25. Colcher A, Simnui T. Other Parkinson syndromes. Neurol Clin. 2001; 19:629-649.
26. Kapur S, Seeman P. Does fast dissociation from the dopamine D (2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-369.
27. Richelson E, Sonder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000:68: 29-39.
28. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39:1-14.
29. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord. 1999;14:1014-1016.
30. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord. 1997;12:119-121.
31. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol. 2000;20:54-60.
32. Leo RJ. Movement disorders associated with the selective serotonin-reuptake inhibitors. J Clin Psychiatry. 1996;57:449-454.
33. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997;31:1481-1489.
34. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692-698.
35. DiRocco A, Brannan T, Prikhojan A, et al. Sertraline-induced parkinsonism: A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm. 1998;105:247-251.
36. Chabolla DR, Maraganore DM, Ahlskog JE, et al. Drug-induced parkinsonism as a risk factor for Parkinson's disease: A historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc. 1998;73:724-727.
37. Gonul AS, Aksu M. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease [letter]. J Clin Psychiatry. 1999;60:410.
38. Stadtland C, Erfurth A, Arolt V. De novo onset of Parkinson's disease after antidepressant treatment with citalopram. Pharmacopsychiatry. 2000;33:194-195.
39. Richard IH, Maughn A, Kurlan R. Do serotonin-reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord. 1999;14:155-157.
40. Kane J, Rifkin A, Quitkyn F, et al. Extrapyramidal side effects with lithium treatment. Am J Psychiatry. 1978;135:851-853.
41. Holroyd S, Smith D. Disabling parkinsonism due to lithium: A case report. J Geriatric Psych Neurol. 1995;8:118-119.
42. Ghadirian AM, Annoble L, Belanger MC, et al. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry. 1996;57:22-28.
43. Muthane UB, Prasad BN, Vasauth A. Tardive parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate. J Neurol Sci. 2000;76:78-79.
44. Lozorsky D, Sailer CF, Kopin IJ. Lithium and the prevention of dopamine receptor supersensitivity in diabetic rats. Am J Psychiatry. 1983;140:613-614.
45. Benazzi F. Parkinson's disease worsened by nefazodone [letter]. Int J Geriatr Psychiatry. 1997;12:1195.
46. Strouse TB, Salehmoghaddam S, Spar JE. Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient. J Clin Psychiatry. 1993;54:489-490.
47. Jerome L. Bupropion and drug-induced parkinsonism. Can J Psychiatry. 2001;46:560-561.
48. Ross RT. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci. 1990;17:155-162.
49. Miller Fisher C. "Catatonia" due to disulfiram toxicity. Arch Neurol. 1989;46:798-804.
50. Laplane D, Attal N, De Billy A, et al. Lesions of the basal ganglia due to disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry. 1992;55:925-929.
51. Kane FJ. Carbon disulfide intoxication from overdosage of disulfiram. Am J Psychiatry. 1970;127:690-694.
52. Van der Zwan A Jr. Transient Parkinson syndrome and tremor caused by the use of sodium valproate. Ned Tijdschr Geneeskd. 1989;133:1230-1232.
53. Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol. 1993;16:451-455.
54. Sasso E, Delsodato S, Negrotti A, et al. Reversible valproate-induced extrapyramidal disorders. Epilepsia. 1994;35:391-393.
55. Onofrj M, Thomas A, Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol. 1998;245:794-796.
56. Masmoudi K, Gras-Champel V, Bonnet I, et al. Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie. 2000;55:629-634.
57. Goni M, Jimenez M, Seijoo M. Parkinsonism-induced by phenytoin. Clin Neuropharmacol. 1985;8:383-384.
58. Marcus D, Kurlan R. Tics and its disorders. Neurol Clin. 2001;19:735-758.
59. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
60. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 1996;57:29-31.
61. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary study. J Am Acad Child Adolesc Psychiatry. 1995;34:1147-1152.
62. Micheli FE, Fernandez-Pardal MM, Gatto M, et al. Flunarizine and cinnarazine-induced extrapyramidal reactions. Neurology. 1987;37:881-884.
63. Garcia-Ruiz PJ, de Yebenes JG, Jimenez-Jimenez FJ, et al. Parkinsonism associated with calcium channel blockers: A prospective follow-up study. Clin Neuropharmacol. 1992;15:19-26.
64. Marti-Masso JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord. 1998;13:453-456.
65. Laporte JR, Capella D. Useless drugs are not placebos: Lessons from flunarizine and cinnarazine. Lancet. 1986;1:853-854.
66. Ambrosio C, Stefanini E. Interaction of flunarazine with dopamine D2 and D1 receptors. Eur J Pharmacol. 1991;197:221-223.
67. Serrano-Duenas M. Parkinsonism or Parkinson's disease unmasked by pentoxifylline? Neurologia. 2001;16:39-42.
68. Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol. 1992;15:322-325.
69. McSwain ML, Forman LM. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol [letter]. J Clin Psychopharmacol 1995;15:284.
70. Cabeza-Alvarez CI, Gonzalez-Rubio M, Garcia-Montero R, et al. Parkinsonian syndrome related to tacrine [in Spanish] [letter]. Neurologia. 1999;14:96.
71. Iwasaki Y, Wakata N, Kinoshita M. Parkinsonism induced by pyridostigmine [letter]. Acta Neurol Scan. 1988;78:236.
72. Fox JH, Bennett DA, Goetz CG, et al. Induction of parkinsonism by intraventricular bethanechol in a patient with Alzheimer's disease. Neurology. 1989;9:1265.
73. Indo T, Ando K. Metoclopramide-induced parkinsonism. Arch Neurol. 1982;39:494-496.
74. Bateman DN, Darling WM, Boys R, et al. Extrapyramidal reactions to metoclopramide and prochlorperazine. QJ Med. 1989;71:307-311.
75. Jimenez-Jimenez FJ, Cabrera Valdivia F, Ayuso Peralta L, et al. Persistent parkinsonism and tardive dyskinesia induced by clebopride. Mov Disord. 1993;8:246-247.
76. Sempere AP, Duarte J, Cabezas C, et al. Aggravation of parkinsonian tremor by cisapride. Clin Neuropharmacol. 1995;18:76-78.
77. Malaterre HR, Lauribe P, Paganelli F, et al. Parkinson syndrome, a possible adverse effect of calcium inhibitors. Arch Mal Coeur Vaiss. 1992;85:1335-1337.
78. Graham DF, Stewart-Wynne EG. Diltiazem-induced acute parkinsonism [letter]. Aust N Z J Med. 1994;24:70.
79. Nakashima K, Shimoda M, Kuno N, et al. Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease. Mov Disord. 1994;9:106-107.
80. Padrell MD, Navarro M, Faura CC, et al. Verapamil-induced parkinsonism [in Spanish]. Am J Med. 1995;99:436.
81. Sempere AP, Duarte J, Cabezas C, et al. Parkinsonism induced by amlodipine. Mov Disord. 1995;10:115-118.
82. Remblier C, Kassir A, Richard D, et al. Parkinson syndrome from diltiazem. Therapie. 2001;56:57-59.
83. Shimoda K, Hikasa C, Nishikawa S, et al. A case report of captopril-induced parkinsonism. Rinsho Shinkeigaku. 1987;27:366-368.
84. Palakurty PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern. Med. 1987;147:881-884.
85. Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol. 1989;25:630-632.
86. Dotti MT, Federico A. Amiodarone-induced parkinsonism: A case report and pathogenetic discussion. Mov Disord. 1995;10:233-234.
87. Malaterre HR, Renou C, Kallee K, et al. Akinesia and amiodarone therapy. Int J Cardiol. 1997;59:107-108.
88. Luque FA, Selhorst JB, Petruska P. Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord. 1987;2:219-222.
89. Howell SJ, Sagar HJ. A progressive parkinsonian syndrome developing after chemotherapy and radiotherapy for non-Hodgkin's lymphoma. Mov Disord. 1994;9:373-375.
90. Kulkantrakorn K, Selhorst JB, Petruska PJ. Cytosine arabinoside and amphotericin B-induced parkinsonism. Ann Neurol. 1996;39:413-414.
91. Wasserstein PH, Honig LS. Parkinsonism during cyclosporine treatment. Bone Marrow Transplant. 1996;18:649-650.
92. Fleming DR, Mangino PB. Parkinsonian syndrome in a dialysis-supported patient receiving high-dose chemotherapy for multiple myeloma. South Med J. 1997;90:364-365.
93. Wiznitzer M, Parker RJ, August CS, et al. Neurological complications of bone marrow transplantation in childhood. Ann Neurol. 1984; 16: 569-576.
94. Mott SH, Packer RJ, Vezin LG, et al. Encephalopathy with parkinsonian features in children following bone marrow transplantation and high-dose amphotericin B. Ann Neurol. 1995;37: 810-814.
95. Pavletic ZS, Bishop MR, Markopoulou K, et al. Drug-induced parkinsonism after allogenic bone marrow transplantation. Bone Marrow Transplant. 1996;17:1185-1187.
96. Lockman LA, Sung JH, Krivit W. Acute parkinsonian syndrome with demyelinating leukoencephalopathy in bone marrow transplant recipients. Pediatr Neurol. 1991;7:457-463.
97. Fischer JF, Dewald J. Parkinsonism associated with intraventricular amphotericine B. J Antimicrob Chemother. 1983;12:97-99.
98. Walker RW, Rosenblum MK. Amphotericin B-associated leukoencephalopathy. Neurology. 1992;42:2005-2010.
99. Balmaceda CM, Walker RW, Castro-Malaspina H. et al. Reversal of amphotericin-B-related encephalopathy. Neurology. 1994;44:1183-1184.
100. Uitti RJ. Advancing Parkinson's disease and treatment of motor complications. In: Adler CH, Ahlskog JE, eds. Parkinson's Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician. Totowa, NJ: Humana Press; 2000:129-149.
101. Mintz U, Lieberman UA, Vries A. Parkinsonism syndrome due to cephaloridine. JAMA. 1971;216:1200.
102. Parmar RC, Valvi CV, Kamat JR, et al. Chloroquine induced parkinsonism. J Postgrad Med. 2000;46:29-30.
103. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979;1:249-254.
104. Langston JW, Ballard PA, Tetrud JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
105. Langston JW, Ballard PA. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine [letter]. N Engl J Med. 1983;309:310.
106. Lieberman AN, Goldstein M. Reversible parkinsonism related to mependine [letter]. N Engl J Med. 1985;312:509.
107. Olive JM, Masana L, Gonzalez J. Meperidine and reversible parkinsonism. Mov Disord. 1994;9:115-116.
108. Klausner JM, Caspi J, Lelcuk S, et al. Delayed muscular rigidity and respiratory depression following fentanyl anesthesia. Arch Surg. 1988; 123:66-67.
109. Goldberg M, Ishak S, Garcia C, et al. Postoperative rigidity following sufentanil administration. Anesthesiology. 1985;63:199-201.
110. Ross RT. Drug-induced parkinsonism and other movement disorders. Can J Neurol Sci. 1990;17:155-162.
111. Gjerris F. Transitory procaine-induced parkinsonism. J Neurol Neurosurg Psychiatry. 1971;34:20-22.
112. Elias MA. Parkinsonian signs may be related to bupivacaine excess. Anesthesiology. 1995;83:224-225.
113. Murachick S, Smith DS. Parkinsonian symptoms during emergence from general anesthesia. Anesthesiology. 1995;82:305-307.
114. El-Maghvobi EA, Eckenhoff RG. Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics. Anesthesiology. 1993;78: 750-756.
115. Euvrard C, Oberlander C, Boissier JR. Antidopaminergic effect of oestrogens at the striatal level. J Pharmacol Exp. 1980;214:179-185.
116. Kulkarni J, Riedel A, de Castella AR, et al. Estrogen - A potential treatment for schizophrenia. Schizophr Res. 2001;48:137-144.
117. Session DR, Pearlstone MM, Jewelwicz R, et al. Estrogens and Parkinson's disease. Med Hypotheses. 1994;42:280-282.
118. Yasui M, Kihira T, Ota K, et al. A case of parkinsonism induced by an oral contraceptive. No To Shinkei. 1992;44:163-166.
119. Masmoudi K, Decocg G, Chetaille E, et al. Extrapyramidal disorders induced by veralipride. Therapie. 1995;50:451-454.
120. Franchignoni FP, Tesio L. Parkinson syndrome induced by veralipride. Minerva Ginecol. 1995;47:277-279.
121. Shaunak S, Brown P, Morgan-Hughes JA. Exacerbation of idiopathic Parkinson's disease by naproxen. BMJ. 1995;311:422.
122. Sandyk R, Gillman MA. Acute exacerbation of Parkinson's disease with sulindac. Ann Neurol. 1985;17:104-105.
123. Enevoldson TP, Wiles CM, Sawle GW. Acute parkinsonism associated with flurbiprofen. BMJ. 1990;300:540.
124. Machtey I. Neurological signs in RA patients receiving gold [letter]. Br J Rheumatol. 1996;35:804.
125. Sugiyama Y. Parkinsonism induced by propiverine hydrochloride-report of 3 cases. Rinsho Shinkeigaku. 1997;37:873-875.
126. Matsuo H, Matsui A, Nasu R, et al. Propiverine-induced parkinsonism: A case report and a pharmacokinetic/pharmacodynamic study in mice. Pharm Res. 2000;17:565-571.
127. Physicians' Desk Reference for Herbal Medicines. 2nd Ed. Montvale, NJ: Medical Economics; 2002.
128. Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf. 1997;16:180-204.
129. Barnes TR, McPhillip MA. Antipsychotic-induced extrapyramidal syndromes: Role of anticholinergic drugs in treatment. CNS Drugs. 1996;6:315-330.
130. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: Clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850-854.